Pfizer gets fresh cancer drug rejection from NICE

LONDON Tue Jul 16, 2013 12:11am BST

People walk past the Pfizer Inc. headquarters in New York, January 31, 2013. REUTERS/Brendan McDermid

People walk past the Pfizer Inc. headquarters in New York, January 31, 2013.

Credit: Reuters/Brendan McDermid

Related Topics

Quotes

   

LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.

The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.

(Reporting by Ben Hirschler; Editing by David Cowell)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.